The DOI matches its Crossref record; 198 of the 202 references it cites were found in a registry or an index.
A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery
Open accessAbstract
Drug repurposing is a strategy consisting of finding new indications for already known marketed drugs used in various clinical settings or highly characterized compounds despite they can be failed drugs. Recently, it emerges as an alternative approach for the rapid identification and development of new pharmaceuticals for various rare and complex diseases for which lack the effective drug treatments. The success rate of drugs repurposing approach accounts for approximately 30% of new FDA approved drugs and vaccines in recent years. This review focuses on the status of drugs repurposing approach for various diseases including skin diseases, infective, inflammatory, cancer, and neurodegenerative diseases. Efforts have been made to provide structural features and mode of actions of drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“One of the main goals of drug repurposing is to shorten the research timeline for discovering new molecules by approximately 50%–60% by utilizing chemically well‐characterized and biologically safe molecules [91].”
From Statins as Antifungal Agents: A Review on Drug Repurposing and Nanotechnology-Driven Delivery Strategies (2025) · cites this paper as [91]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
A comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · cited 1×
“neurochemical changes in the brain, are the crucial pathological event for AD [137].”
The Genome Sequence of the SARS-Associated Coronavirus
Marra, M. A., Jones, S. J. M., Astell, C. R., Holt, R. A., Brooks-Wilson, A. R., Butterfield, Y. S. N., Khattra, J. S., Asano, J. K., Barber, S., Chan, S. Y., et al. (2003) · Science · doi:10.1126/science.1085953 · Cited by 2,027
Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821
Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
Simmons, D. L., Botting, R. M., & Hla, T. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.3.3 · Cited by 1,718
Rothwell, P. M., Fowkes, F. G. R., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62110-1 · Cited by 1,497
Research works printed but not linked: 4
- Gilbert, 2003, Rebuilding big pharma’s business model, in vivo, The Business Med. Rep., 21, 73
- Broughton, 2012, Statin use is associated with a reduced incidence of colorectal cancer: a colonoscopy-controlled case-control study, BMC Gastroenterol., 12, 36, 10.1186/1471-230X-12-36 · DOI
- Regnard, 2011, vol. 42, 319
- Pagan, 2016, vol. 6, 503
Cited by
Sorted by citations
Drug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
“24 Historically, drug repurposing in oncology has largely been driven by either an understanding of the disease pathways or through serendipitous fi ndings.”
BackgroundUtilizing graph machine learning within drug discovery and development
Gaudelet, T., Day, B., Jamasb, A. R., Soman, J., Regep, C., Liu, G., Hayter, J. B. R., Vickers, R., Roberts, C., Tang, J., et al. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab159 · Cited by 313
Hung, S. W., Zhang, R., Tan, Z., Chung, J. P. W., Zhang, T., & Wang, C. C. (2021) · Medicinal Research Reviews · doi:10.1002/med.21802 · Cited by 175
Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers
Begley, C. G., Ashton, M. R., Baell, J. B., Bettess, M. D., Brown, M. P., Carter, B. A., Charman, W. N., Davis, C., Fisher, S., Frazer, I. H., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd5524 · Cited by 164
Utilizing drug repurposing against COVID-19 – Efficacy, limitations, and challenges
Parvathaneni, V., & Gupta, V. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118275 · Cited by 138
Metadata
- Authors
- Pillaiyar, T., Meenakshisundaram, S., Manickam, M., & Sankaranarayanan, M.
- Affiliations
- University of Bonn (DE)
- PSG INSTITUTE OF TECHNOLOGY AND APPLIED RESEARCH (IN)
- Corresponding author
- Pillaiyar, Thanigaimalai
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 195
- Pages
- 112275
- ISSN
- 0223-5234 (ISSN-L)
- PMC
- PMC7156148
- OpenAlex
- W3013498471
- Cited by
- 140
- References
- 202
- Citations by year
- 2026: 13 · 2025: 25 · 2024: 18 · 2023: 25 · 2022: 26 · 2021: 15 · 2020: 17
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Journal of Medicinal Chemistry (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- PSG
- PSG Institute of Technology and Applied Research
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- drug repurposing, marketed drugs, rare diseases, skin diseases, infectious diseases, inflammatory diseases, cancer, neurodegenerative diseases, structural features, mechanism of action
- MeSH terms
- Animals, Chemistry, Pharmaceutical, Humans, Drug Discovery, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
